alexa
Reach Us +1-504-608-2390
A Novel Non-integrative One-cycle Lentiviral Genome Derived From A Naturally Attenuated Animal Lentivirus As HIV-1 Vaccine | 3253
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A novel non-integrative one-cycle lentiviral genome derived from a naturally attenuated animal lentivirus as HIV-1 vaccine


Y. Chebloune, G. Arrode-Bruses, M. Moussa, D. Aldebert, B. Ouzrout, M De Gasperi, A. Malogolovkin, A. Smaoune and Lina Khelifeh

: J Vaccines Vaccin

Abstract
Development of safe and efficacious HIV vaccines remains a priority to stop the epidemics in humans. Protective immunity induced by live-attenuated viruses in macaques against highly pathogenic challenge viruses provided the proof of the concept of such a strategy. DNA vaccines are potent inducers of virus-specific T cell responses, and studies have shown that alone or with recombinant viral vaccines, DNA vaccines can provide protection against challenges with homologous pathogenic AIDS viruses. Therefore, novel safe DNA vaccines and strategies that mimic natural lentivirus infection are hardly needed to generate safe and efficacious HIV vaccines. We have developed lentivectors as DNA vaccines and have shown that they were efficient alone at inducing unique T cell responses and protection of vaccinated macaques from AIDS against a homologous pathogenic virus. We engineered a novel one-cycle replication non-integrative lentivector driven by the 5? and 3? LTRs from the genome of a naturally attenuated lentivirus of goats, CAEV, that have constitutive promoters. This vaccine was shown to express all viral proteins that were assembled into viral particles which undergo a unique cycle of replication in cell culture systems. We NOD/ SCID-γ2-hu mice and macaques with our vaccine DNA and showed that all animals developed potent antigen specific immune responses that we characterized longitudinally. Interestingly, the kinetics of induced T cell responses correlated with the kinetics of virus antigen expression. In our ongoing longitudinal study we are closely monitoring the development of the induced antigen- immune responses prior to challenge experiments.
Biography
Yahia Chebloune has completed his Ph.D at the age of 30 years from Claude Bernard Lyon-1 University and postdoctoral studies from University of Kansas School of Medicine. He is Research director at the CNRS and Joseph Fourier University of Grenoble, leading the group of Pathogenesis and Lentivirus Vaccination. He has published more than 80 papers in reputed journals and serving as an editorial board member of repute. His recent work is focusing on development of HIV-1 vaccine using the naturally attenuated animal lentivirus, CAEV as model and to study the mechanisms involved in latency/persistence of HIV/SIV in relation with pathogenesis.
Top